New Data Released At ISHLT Meeting May Impact Treatment for Patients With Pulmonary Arterial Hypertension

Published: Apr 19, 2012

PRAGUE, Czech Republic, April 19, 2012 (GLOBE NEWSWIRE) -- An initial report from the EPITOME-1 (Epoprostenol for Injection in Pulmonary Arterial Hypertension) study of a new formulation of the drug therapy epoprostenol, marketed as FlolanĀ® will be revealed today at the International Society for Heart and Lung Transplantation (ISHLT) 32nd Annual Meeting and Scientific Sessions in Prague, Czech Republic. The findings could potentially allow patients living with Pulmonary Arterial Hypertension (PAH) to avoid the need for using ice packs to prepare and store up to seven days worth of medication in the refrigerator.

Back to news